Conmed (CNMD) Tops Q1 EPS by 3c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
CONMED (CNMD) PT Raised to $95 at Needham & Company
April 25, 2019 8:26 AM EDTNeedham & Company analyst Mike Matson raised the price target on CONMED (NASDAQ: CNMD) to $95.00 (from $94.00) while maintaining a Buy rating.
The analyst commented, " CNMD's 1Q19 revenue and EPS beat consensus. Given the recent Buffalo Filter acquisition, management provided 2019 revenue guidance and also raised its... More
